Human Apolipoprotein CIII, Low Endotoxin Level

1. Home
2. Proteins
3. Human Proteins

Product Overview, Sizes and Prices
	Proteins Synonyms: ApoCIII, ApoC3 Source: Human Plasma Purity: ≥ 95% by SDS-PAGE Endotoxin Level: ≤1 EU/mg Physical State: Frozen in 10 mM NH4HCO3, pH 7.4 Manufacturer:  Athens Research & Technology	Article No. Size Price   16-16-120303-LEL-100UG 100 µg 205 € 16-16-120303-LEL-1MG 1 mg 1.375 € Please inquire for other vial sizes and custom vialing.

 

 

Produktdetails

Synonyms

ApoCIII, ApoC3

 

Description of Human Apolipoprotein CIII, Low Endotoxin Level

Human Apolipoprotein CIII, Low Endotoxin Level is a 8.75 kDa protein. Apolipoprotein CIII (ApoCIII) is a 79-amino acid glycoprotein primarily synthesized in the liver and intestine, circulating on triglyceride-rich lipoproteins (TRLs) such as VLDL, chylomicrons, and HDL. Functionally, ApoCIII inhibits lipoprotein lipase (LPL) activity by displacing its activator ApoCII, thereby reducing triglyceride hydrolysis and delaying hepatic clearance of TRLs via LDL receptor-related protein 1 (LRP1) and syndecan-1 pathways. It also promotes VLDL secretion under lipid-rich conditions, exacerbating hypertriglyceridemia. Clinically, elevated ApoCIII levels (>15 mg/dL) correlate with hypertriglyceridemia, atherosclerosis, and coronary heart disease, while loss-of-function variants reduce cardiovascular risk by 40%. ApoCIII overexpression induces insulin resistance by impairing skeletal muscle glucose uptake and pancreatic β-cell function, with elevated plasma levels predicting type 2 diabetes progression. Therapeutically, ApoCIII is targeted using antisense oligonucleotides (e.g., volanesorsen), which lower triglycerides by 70–80% in familial chylomicronemia syndrome, and RARα agonists like AM580 that suppress hepatic ApoCIII synthesis via HNF4α downregulation. Synthetic ApoCII mimetics (C-II-a) counteract ApoCIII-mediated LPL inhibition3, while dual APOC3/APOB gene silencing strategies show promise for combined dyslipidemias. Normal plasma concentrations (8–15 mg/dL) serve as biomarkers for cardiovascular risk stratification, particularly in diabetic populations. Emerging evidence positions ApoCIII inhibition as a dual therapeutic approach for metabolic and cardiovascular diseases.

 

Source

Prepared from fresh, non-frozen plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

 

Storage

For long term, store Human Apolipoprotein CIII, Low Endotoxin Level at ≤ -80°C.

 

Applications

Cell Based Assays, Animal Studies, In Vitro Diagnostics, Cardiovascular Research, Diabetes.

 

Citations/Publications

NCBI: https://www.ncbi.nlm.nih.gov/protein/P02656

 

Shipped with dry ice

 

 

 

 

 

Usage: For research use only. Not for use in diagnostic or therapeutic procedures. Not for human use.

 

To buy Human Apolipoprotein CIII, Low Endotoxin Level please click on the Shopping List Symbol right from the indicated price. This will add Human Apolipoprotein CIII, Low Endotoxin Level to your Shopping List. You can then click on the button »Shopping List & Order Form« to ask for a quote. We will send you your quote as soon as possible. Our offer will include institutional discounts where applicable.

 

 

For business customers only. All prices are net prices (excluding VAT). Final prices in our quote will contain VAT plus shipping costs if applicable. For further information please go to our Shipping page.

 

Errors, changes and availability excepted.